$9.59
0.36% yesterday
Nasdaq, Nov 25, 10:02 pm CET
ISIN
US03828A1016
Symbol
APLT
Sector
Industry

Applied Therapeutics, Inc. Stock price

$9.59
+1.16 13.76% 1M
+5.51 135.05% 6M
+6.24 186.27% YTD
+7.75 421.20% 1Y
-1.52 13.68% 3Y
-6.40 40.03% 5Y
+0.19 2.02% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.04 0.36%
ISIN
US03828A1016
Symbol
APLT
Sector
Industry

Key metrics

Market capitalization $1.12b
Enterprise Value $993.87m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 93.23
P/S ratio (TTM) P/S ratio 104.68
P/B ratio (TTM) P/B ratio 189.38
Revenue (TTM) Revenue $10.66m
EBIT (operating result TTM) EBIT $-62.50m
Free Cash Flow (TTM) Free Cash Flow $-54.06m
Cash position $98.87m
EPS (TTM) EPS $-1.32
P/E forward negative
P/S forward 586.19
EV/Sales forward 522.11
Short interest 11.65%
Show more

Is Applied Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Applied Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Applied Therapeutics, Inc. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Applied Therapeutics, Inc. forecast:

Buy
100%

Financial data from Applied Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
11 11
-
100%
- Direct Costs 0.46 0.46
5% 5%
4%
10 10
2,418% 2,418%
96%
- Selling and Administrative Expenses 22 22
30% 30%
202%
- Research and Development Expense 51 51
14% 14%
476%
-62 -62
32% 32%
-582%
- Depreciation and Amortization 0.46 0.46
5% 5%
4%
EBIT (Operating Income) EBIT -63 -63
31% 31%
-586%
Net Profit -97 -97
1% 1%
-905%

In millions USD.

Don't miss a Thing! We will send you all news about Applied Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Applied Therapeutics, Inc. Stock News

Positive
Seeking Alpha
2 months ago
Applied Therapeutics, Inc.'s stock surged nearly 70% yesterday after the news that the FDA will not hold an AdCom to discuss approval of AT-007 in galactosemia. AT-007 has shown clinical benefits in galactosemia and SORD deficiency, and its PDUFA for the former arrives at the end of November. With no AdCom, approval seems the likeliest outcome. Despite financial constraints, strong patient and ...
Positive
Seeking Alpha
2 months ago
FDA removes the need for an advisory panel to first give a recommendation review of Applied Therapeutics, Inc.'s govorestat for the treatment of patients with galactosemia. PDUFA date of November 28th, 2024, remains on track for the FDA to decide whether govorestat should be approved to treat patients with galactosemia. Pre-NDA meeting with FDA expected in 2nd half of 2024 to discuss possible a...
Positive
The Motley Fool
2 months ago
The FDA won't hold an Advisory Committee meeting to review Applied Therapeutics' regulatory filing for govorestat. This move could increase the likelihood that the drug will win FDA approval.
More Applied Therapeutics, Inc. News

Company Profile

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Head office United States
CEO Shoshana Shendelman
Employees 25
Founded 2016
Website www.appliedtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today